Could some breast cancer patients avoid surgery? new trial explores the possibility
NCT ID NCT06938724
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The goal is to see if avoiding these local treatments is as safe as standard care for these highly selected patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Omission of surgery or radiotherapy
What this could lead to
If successful, this could show that some women with these breast cancer types can avoid surgery or radiation after a complete response to chemotherapy, reducing treatment burden.
What could go wrong
This is a small, early-phase trial with only 152 participants. It is not yet proven that skipping local therapies is safe, and there is a risk of cancer returning without these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale Tumori Milano
RECRUITINGMilan, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••